Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

1. Valcarcel, S.
2. Gallego, J.
3. Jimenez-Fonseca, P.
4. Diez, M.
5. de Castro, E.M.
6. Hernandez, R.
7. Arrazubi, V.
8. Custodio, A.
9. Cano, J.M.
10. Montes, A.F.
11. Macias, I.
12. Visa, L.
13. Calvo, A.
14. Tocino, R.V.
15. Lago, N.M.
16. Limón, M.L.
17. Granja, M.
18. Gil, M.
19. Pimentel, P.
20. Macia-Rivas, L.
21. Pérez, C.H.
22. Mangas, M.
23. Carnicero, A.M.
24. Cerdà, P.
25. Gonzalez, L.G.
26. Navalon, F.G.
27. Rambla, M.ªD.M.
28. Richard, M.M.
29. Carmona-Bayonas, A.
30. Show all authors +